Becton Dickinson and Co (BDX) Shares Sold by Exxonmobil Investment Management Inc. TX

Exxonmobil Investment Management Inc. TX cut its holdings in Becton Dickinson and Co (NYSE:BDX) by 12.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 36,250 shares of the medical instruments supplier’s stock after selling 5,307 shares during the period. Exxonmobil Investment Management Inc. TX’s holdings in Becton Dickinson and were worth $7,760,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Koch Industries Inc. boosted its position in Becton Dickinson and by 45,268.7% during the second quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock worth $1,391,000 after purchasing an additional 1,395,182 shares during the period. Vanguard Group Inc. boosted its position in shares of Becton Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after acquiring an additional 1,353,780 shares during the period. Winslow Capital Management LLC bought a new stake in shares of Becton Dickinson and in the second quarter valued at about $225,164,000. Janus Henderson Group PLC boosted its position in shares of Becton Dickinson and by 1,265.9% in the second quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after acquiring an additional 1,122,191 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Becton Dickinson and by 216.2% in the second quarter. Parametric Portfolio Associates LLC now owns 1,320,259 shares of the medical instruments supplier’s stock valued at $257,596,000 after acquiring an additional 902,761 shares during the period. Institutional investors own 75.69% of the company’s stock.

Several research firms recently weighed in on BDX. Bank of America reaffirmed a “buy” rating and set a $260.00 price objective on shares of Becton Dickinson and in a research report on Friday, January 19th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price objective for the company in a research report on Friday, January 19th. Stifel Nicolaus reissued a “buy” rating and set a $245.00 target price on shares of Becton Dickinson and in a research note on Friday, November 3rd. Royal Bank of Canada reissued a “sector perform” rating and set a $230.00 target price (up previously from $210.00) on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Morgan Stanley upped their price objective on Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $233.80.

Becton Dickinson and Co (NYSE BDX) traded down $1.42 during midday trading on Thursday, reaching $241.52. The company had a trading volume of 1,109,367 shares, compared to its average volume of 1,492,167. The stock has a market cap of $64,872.12, a price-to-earnings ratio of 51.94, a P/E/G ratio of 1.74 and a beta of 1.07. Becton Dickinson and Co has a twelve month low of $175.66 and a twelve month high of $248.39. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. During the same period in the prior year, the firm posted $2.12 EPS. Becton Dickinson and’s quarterly revenue was down 2.0% compared to the same quarter last year. research analysts anticipate that Becton Dickinson and Co will post 10.92 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.24%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is presently 64.52%.

TRADEMARK VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Shares Sold by Exxonmobil Investment Management Inc. TX” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/01/exxonmobil-investment-management-inc-tx-sells-5307-shares-of-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply